CT imaging changes of corona virus disease 2019(COVID-19): a multi-center study in Southwest China

Li, Xiaoming; Zeng, Wenbing; Li, Xiang; Chen, Haonan; Shi, Linping; Li, Xinghui; Xiang, Hongnian; Cao, Yang; Chen, Hui; Liu, Chen; Wang, Jian

doi:10.1186/s12967-020-02324-w

Cited by 156 publications

(89 citation statements)

References 23 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Others were from sputum, with four (15)(16)(17)37) from a nasopharyngeal swab and two (4, 37) from a cerebrospinal fluid (CSF) sample (26). Six studies (10,(32)(33)(34)(35)(36) did not report the specimen used. Five studies (4, 14-16, 37) used more than one type of specimen collected.…”

Section: Study Results and Patient Characteristicsmentioning

confidence: 99%

Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Importance: Coronavirus disease 2019 (COVID-19) is a newly emerging infectious disease that has caused a global pandemic. The presenting symptoms are mainly respiratory symptom, yet studies have reported nervous system involvement in the disease. A systematic review and meta-analysis of these studies are required to understanding the neurologic characteristic of the disease and help physicians with early diagnosis and management. Objective: To conduct a systematic review and meta-analysis on the neurologic characteristics in patients with COVID-19. Evidence Review: Authors conducted a literature search through PubMed from January 1st, 2020 to April 8th, 2020. Furthermore, the authors added additional sources by reviewing related references. Studies presenting the neurologic features of COVID-19 patients in their data were included. Case reports and case series were also included in this review. The quality of the studies was assessed based on the Oxford Center for Evidence-Based Medicine guidelines. Selected studies were included in the meta-analysis of proportion and the heterogeneity test. Finding: From 280 identified studies, 33 were eligible, with 7,559 participants included. Most of the included studies were from China (29 [88%]). Muscle injury or myalgia was the most common (19.2%, 95%CI 15.4-23.2%) neurologic symptom of COVID-19, followed by headache (10.9%, 95%CI 8.62-13.51%); dizziness (8.7%, 95%CI 5.02-13.43%); nausea with or without vomiting (4.6%, 95%CI 3.17-6.27%); concurrent cerebrovascular disease (4.4%, 95%CI 1.92-7.91%); and impaired consciousness (3.8%, 95%CI 0.16-12.04%). Underlying cerebrovascular disease was found in 8.5% (95%CI 4.5-13.5%) of the studies. Conclusion: Neurologic findings vary from non-specific to specific symptoms in COVID-19 patients. Some severe symptoms or diseases can present in the later stage of the disease. Physicians should be aware of the presence of neurologic signs and symptoms as a chief complaint of COVID-19, in order to improve management and prevent a worsening outcome of the patients.

show abstract

Section: Study Results and Patient Characteristicsmentioning

confidence: 99%

Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This study revealed the usefulness of AI approach to support the diagnosis of COVID-19, but also for future emerging diseases [134]. All the collected knowledge on lung lesions revealed some characteristic CT findings of COVID-19 pneumonia: the pulmonary ground-glass opacities in a peripheral distribution and the consolidation referring to an increase in pulmonary parenchymal density [135][136][137]. However, chest CT manifestations can vary in different patients and stages of infection, highlighting certain shortcomings of this approach.…”

Section: Ct Scans and Serology Methodsmentioning

confidence: 99%

The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting

Hozhabri

Piceci‐Sparascio

Sohrabi

et al. 2020

IJERPH

View full text Add to dashboard Cite

Over the past two decades, there have been two major outbreaks where the crossover of animal Betacoronaviruses to humans has resulted in severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). In December 2019, a global public health concern started with the emergence of a new strain of coronavirus (SARS-CoV-2 or 2019 novel coronavirus, 2019-nCoV) which has rapidly spread all over the world from its origin in Wuhan, China. SARS-CoV-2 belongs to the Betacoronavirus genus, which includes human SARS-CoV, MERS and two other human coronaviruses (HCoVs), HCoV-OC43 and HCoV-HKU1. The fatality rate of SARS-CoV-2 is lower than the two previous coronavirus epidemics, but it is faster spreading and the large number of infected people with severe viral pneumonia and respiratory illness, showed SARS-CoV-2 to be highly contagious. Based on the current published evidence, herein we summarize the origin, genetics, epidemiology, clinical manifestations, preventions, diagnosis and up to date treatments of SARS-CoV-2 infections in comparison with those caused by SARS-CoV and MERS-CoV. Moreover, the possible impact of weather conditions on the transmission of SARS-CoV-2 is also discussed. Therefore, the aim of the present review is to reconsider the two previous pandemics and provide a reference for future studies as well as therapeutic approaches.

show abstract

“…There is a wide range of clinical presentations of COVID-19-infected patients, varying from asymptomatic recovery to critical illness and death. Classically, patients with COVID-19 present with cough, fever, dyspnea, fatigue, and respiratory failure along with multiorgan damage in severe cases [4][5][6]. The disease is highly contagious and spreads in cluster outbreaks.…”

Section: Introductionmentioning

confidence: 99%

The Dilemma of Renal Involvement in COVID-19: A Systematic Review

Bajwa¹,

Riaz²,

Ammar³

et al. 2020

Cureus

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), now known as coronavirus disease 2019 (COVID-19), has posed a serious threat to global health since December 2019. It has spread worldwide and is consuming healthcare resources rapidly. Published literature suggests that people with advanced age and comorbidities are affected more severely. It is crucial to uncover the underlying pathogenesis of acute kidney insufficiency in COVID-19 patients to understand better the reasoning behind the grave outcomes in these patients. In this review, we have included articles stating the prevalence and specific mortality rates of COVID-19 patients with acute kidney insufficiency. Our study included 1098 COVID-19 positive patients, of whom 66 (6%) developed acute kidney insufficiency and 62 patients died, showing a mortality rate of 94%. Patients with acute kidney insufficiency showed a more severe disease course, and these patients ended up more in intensive care units. Particular attention should be paid to those with already established kidney disease, such as chronic kidney disease, or renal transplant recipients, as these patients are already on immunosuppressive therapy. Our review focuses on the prevalence of acute kidney insufficiency in COVID-19 patients and mortality rates in this subset of patients.

show abstract

CT imaging changes of corona virus disease 2019(COVID-19): a multi-center study in Southwest China

Cited by 156 publications

References 23 publications

Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting

The Dilemma of Renal Involvement in COVID-19: A Systematic Review

Contact Info

Product

Resources

About